Differential immunohistochemical expression of syndecan-1 and tumor necrosis factor alpha in colonic mucosa of patients with Crohn's disease

Immunopharmacology and Immunotoxicology

Volumn 28, Issue 2, 2006, Pages 185-195

  Principi, Mariabeatrice ^a   Day, Richard ^b   Marangi, Stefania ^c   Burattini, Osvaldo ^c   De Francesco, Vincenzo ^a   Ingrosso, Marcello ^c   Pisani, Antonio ^c   Panella, Carmine ^d   Forbes, Alastair ^b   Di Leo, Alfredo ^c   Francavilla, Antonio ^c   Ierardi, Enzo ^d  

^a OSPEDALI RIUNITI   (Italy)

^b ST MARK S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BARI   (Italy)

^d UNIVERSITY OF FOGGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

SYNDECAN 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BASOLATERAL MEMBRANE; CELL LABELING; CLINICAL ARTICLE; COLON BIOPSY; COLON CROHN DISEASE; COLON MUCOSA; COMPARATIVE STUDY; CONTROLLED STUDY; CROHN DISEASE; FEMALE; HUMAN; HUMAN TISSUE; INTESTINE CRYPT; IRRITABLE COLON; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STROMA CELL; TISSUE SECTION;

EID: 33746820209     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.1080/A08923970600815048     Document Type: Article

References (30)

1. Murch, S.H.; Braegger, C.P.; Walker-Smith, J.A.; MacDonald, T.T. Location of tumor necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993, 34(12), 1705-1709.
2. Dionne, S.; Hiscott, J.; D'Agata, I.D.; Duhaime, A.; Seidman, E.G. Quantitative PCR analysis of TNFα and IL-1β mRNA levels in pediatric IBD mucosal biopsies. Dig. Dis. Sci. 1997, 42(7), 1557-1566.
3. Rugtveit, J.; Nilsen, E.M.; Bakka, A.; Carlsen, H.; Brandtzaeg, P. Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease. Gastroenterology 1997, 112(5), 1493-1505.
4. van Dullemen, H.M.; van Deventer, S.J.; Hommes, D.W.; Bijl, H.A.; Jansen, J.; Tytgat, G.N.; Woody, J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody cA2. Gastroenterology 1995, 109(1), 129-135.
5. Baert, F.J.; D'Haens, G.R.; Peeters, M.; Hiele, M.I.; Schaible, T.F.; Shealy, D.; Geboes, K.; Rutgeerts, P.J. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis Gastroenterology 1999, 116(1), 22-28.
6. Haier, J.; Nicolson, G.L. Cell biology and clinical implications of adhesion molecules in colorectal diseases: colorectal cancers, infections and inflammatory bowel diseases. Clin. Exp. Metast. 2000, 18(5), 623-638.
7. Neurath, M.F.; Schurmann, G. Immunopathogenesis of inflammatory bowel diseases. Chirurg 2000, 71(1), 30-40.
8. Day, R.; Ilyas, M.; Daszak, P.; Talbot, I.; Forbes, A. Expression of Syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy Dig. Dis. Sci. 1999, 44(12), 2508-2515.
9. Saunders, S.; Jalkanen, M.; O'Farrell, S.; Bernfield, M. Molecular cloning of syndecan, an integral membrane proteoglycan. J. Cell Biol. 1989, 108(2), 1547-1556.
10. Day, R.; Forbes, A. Heparin, cell adhesion, and pathogenesis of inflammatory bowel diasease. Lancet 1999, 354(July 3), 62-64.
11. Day, R.; Mitchell, T.; Knight, S.; Forbes, A. Regulation of epithelial syndecan-1 expression by inflammatory cytokine. Cytokines 2003, 21(5), 224-233.
12. Kainulainen, V.; Nelimarkka, L.; Järveläinen, H.; Laato, M.; Jalkanen, M.; Elenius, K. Suppression of Syndecan-1 expression in endothelial cells by tumor necrosis factor-α. J. Biol. Chem. 1996, 271(31), 18759-18766.
13. Ierardi, E.; Di Leo, A.; Barone, M.; Marangi, S.; Burattini, O.; Panarese, A.; Margiotta, M.; Francavilla, R.; Panella, A.; Francavilla, A.; Cuomo, R. Tumor necrosis factor alpha and apoptosis related progressive gastric damage: a possibile mechanism of immune system involvement in epithelial turnover regulation. Immunopharmacol. Immunotoxicol. 2003, 25(2), 203-211.
14. Ierardi, E.; Monno, R.A.; Gentile, A.; Francavilla, R.; Burattini, O.; Marangi, S.; Pollice, L.; Francavilla, A. Helicobacter heilmannii gastritis: a histological and immunohistochemical trait. J. Clin. Pathol. 2001, 54(11), 774-777.
15. Day, R.; Hao, X.; Ilyas, M.; Daszak, P.; Talbot, I.; Forbes, A. Changes in the expression of syndecan-1 in the colorectal adenoma-carcinoma sequence. Virchows Arch 1999, 434(2), 121-125.
16. Fiocchi, C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998, 115(1), 182-205.
17. Wyatt, J.; Vogelsang, H.; Hubl, W.; Waldhoer, T.; Lochs, H. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993, 341(June 5), 1437-1439.
18. Yayon, A.; Klagsbrun, M.; Esko, J.; Leder, P.; Ornitz, D. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991, 64(34), 841-848.
19. Dignass, A.U. Mechanisms and modulation of intestinal epithelial repair Inflamm. Bowel Dis. 2001, 7(1), 68-77.
20. Ruemmele, F.M.; Seidman, E.G. Cytokine-intestinal epithelial cell interactions: implication for immune-mediated bowel disorders. Acta Paediatr. Sin. 1998, 39(1), 1-8.
21. Ierardi, E.; Principi, M.; Burattini, O.; Marangi, S.; Panarese, A.; Francavilla, A. Pattern of apoptosis in Crohn's disease: a singular aspect? Dig. Liver. Dis. 2001, 33(7), 614-615.
22. Braegger, C.P.; Nicholls, S.; Murch, S.H.; Stephens, S.; MacDonald, T.T. Tumor necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992, 339(Jan 11), 89-91.
23. Papadakis, K.A.; Targan, S.R. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000, 119(4), 1148-1457.
24. Targan, S.R.; Hanauer, S.B.; van Deventer, S.J.; Mayer, L.; Present, D.H.; Braakman, T.; DeWoody, K.L.; Schaible, T.F.; Rutgeerts, P.J. A short term study of chimeric monoclonal antibody cA2 to tumour necrosis factor alpha for Crohn's disease. N. Engl. J. Med. 1997, 337(15), 1029-1035.
25. Rutgeerts, P.; D'Haens, G.; Targan, S.; Vasiliauskas, E.; Hanauer, S.B.; Present, D.H.; Mayer, L.; Von Hogezand, R.A.; Braakman, T.; DeWoody, K.L.; Schaible, T.F.; Van Deventer, S.J. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999, 117(4), 761-769.
26. Sartor, R.B. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol. Clin. North. Am. 1995, 24(3), 475-507.
27. MacDonald, T.T.; Hutchings, P.; Choy, M.; Murch, S.; Cooke, A. Tumor necrosis factor alpha and interferon-gamma productions measured at the single cell level in normal and inflamed human intestine. Clin. Exp. Immunol. 1990, 81(2), 301-305.
28. Perry, I.; Tselepis, C.; Hoyland, J.; Iqbal, T.; Sanders, S.; Cooper, I.J.; Jankowski, J.A. Reduced cadherin/catenin complex expression in celiac disease can be reproduced in vitro by cytokine stimulation. Lab. Invest. 1999, 79(12), 1489-1499.
29. Yacyshyn, B.R.; Barish, C.; Goff, J.; Dalke, D.; Gaspari, M.; Yu, R.; Tami, J.; Dorr, F.A.; Sewell, K.L. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. Aliment Pharmacol. Ther. 2002, 16(10), 1761-1770.
30. Folwaczny, C.; Wiebecke, B.; Loeschke, K. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease Am. J. Gastroenterol. 1999, 94(6), 1551-1555.